Rocket Pharmaceuticals, Inc. (RCKT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 31.32M USD | Liabilities, Current |
| Cash and equivalents | 224.51M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $31.32M | $224.51M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $24.47M | $49.61M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $30.21M | $77.56M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $31.17M | $75.95M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $43.40M | $32.82M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $35.31M | $49.81M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $40.68M | $163.63M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $39.98M | $65.60M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $37.59M | $38.61M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $32.96M | $35.28M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $48.51M | $55.90M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $33.48M | $225.66M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $34.35M | $45.08M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $31.21M | $64.58M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $39.17M | $140.52M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $30.18M | $196.67M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $24.29M | $187.55M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $22.57M | $130.55M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $22.17M | $232.69M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $24.49M | $245.64M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $25.44M | $264.61M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $40.49M | $252.54M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $32.62M | $297.10M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $31.95M | $82.23M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $20.68M | $163.20M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $21.11M | $190.52M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $18.31M | $185.38M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $22.18M | $89.19M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $15.08M | $64.83M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $20.57M | $124.46M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $15.37M | $111.36M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $10.29M | $38.08M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $10.15M | $52.55M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $7.34M | $171.14M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $4.07M | $78.72M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $3.77M | $49.15M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $4.02M | $27.61M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $5.27M | $25.27M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $7.21M | $29.80M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $5.94M | $83.00M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $4.07M | $38.52M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $4.61M | $58.71M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $4.14M | $80.04M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $3.24M | $89.25M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $2.45M | $49.01M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $2.46M | $53.14M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $7.22M | $3.62M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $5.36M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $8.88M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $10.94M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $12.79M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |